Healthcare

The execution of different test methods aiming to evaluate the stability and potency of biopharmaceutical products, as well as, their pharmacokinetic/pharmacodynamic (PK/PD) profiles, their characterization and comparison with other drugs, or the detection of antidrug antibodies (ADAs) or neutralizing antibodies (NAB), represent critical stages in ...

This study investigates the global stem cell market for the period 2013 to 2018. The geographic regions covered in the study are the North America, Europe and APAC, followed by a detailed Asia Pacific Region Analysis, which covers countries such as India, Australia, Thailand, Singapore, South Korea, Malaysia and Japan. The stem cell market is cover...

This issue of Vital Signs, released on October 3, 2014, discusses Merck KGaAs acquisition of Sigma-Aldrich, highlights from the 2014 AACC Meeting, Abbotts CE Mark for FreeStyle® Libre, laboratory developed test (LDT) regulations, and the sale of Fortis Healthcares Singapore subsidiary, RadLink-Asia Pte Ltd, and its arm, RadLink Singapore.

This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biologys Series A funding round, Roches investment in Stratos Genomics, and Indias cap on drug prices.

This issue of Vital Signs, released on July 11, 2014, discusses game changing strategies in clinical research, including virtual clinical research organization (CRO) and the integrated business model.

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinica...

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogens Eloctate, Qiagens acquisition of Primera Dx, Roches acquisition of Genia Technologies, Cues at-home connected lab test, and the Credihealth Teen Clinic.

The total market, as defined by this study, includes next-generation sequencing instruments and reagents. Instruments include those that use newer technology than traditional capillary electrophoresis (CE) sequencing, such as sequencing-by-synthesis, sequencing-by-ligation, single-molecule sequencing, and semiconductor sequencing. This research ser...